カルボプラチンとパクリタキセル、またはオキサリプラチンとカペシタビンにベバシズマブを併用または非併用で、新たに診断されたステージ II~IV または再発ステージ I の上皮性卵巣がんまたは卵管がん患者の治療における第一選択療法として
非盲検カルボプラチンおよびパクリタキセル +/- NCI 供給薬剤の GCIG Intergroup 多施設共同第 III 相試験: ベバシズマブ (NSC #704865) をオキサリプラチンおよびカペシタビン +/- ベバシズマブと比較して、粘液性上皮性卵巣癌または卵管癌患者の第一選択化学療法として(MEOC)
This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II-IV, or recurrent (has come back) stage I epithelial ovarian or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known which regimen of combination chemotherapy given together with or without bevacizumab is more effective in treating epithelial ovarian cancer or fallopian tube cancer.
調査の概要
状態
条件
- 再発卵管がん
- 再発性卵巣癌
- ステージ IA 卵管がん AJCC v6 および v7
- ステージ IA 卵巣がん AJCC v6 および v7
- ステージ IB 卵管がん AJCC v6 および v7
- IB 期の卵巣がん AJCC v6 および v7
- ステージ IC 卵管がん AJCC v6 および v7
- ステージ IC の卵巣がん AJCC v6 および v7
- ステージ IIA の卵管がん AJCC v6 および v7
- ステージ IIA の卵巣がん AJCC V6 および v7
- ステージ IIB 卵管がん AJCC v6 および v7
- ステージ IIB の卵巣がん AJCC v6 および v7
- IIC 期の卵管がん AJCC v6 および v7
- IIC 期の卵巣がん AJCC v6 および v7
- IIIA 期卵管がん AJCC v7
- ステージ IIIA の卵巣がん AJCC v6 および v7
- ステージ IIIB 卵管がん AJCC v7
- ステージ IIIB の卵巣がん AJCC v6 および v7
- ステージ IIIC の卵管がん AJCC v7
- ステージ IIIC の卵巣がん AJCC v6 および v7
- ステージ IV 卵管がん AJCC v6 および v7
- ステージ IV の卵巣がん AJCC v6 および v7
- 卵巣粘液性嚢胞腺癌
- 境界性卵巣粘液性腫瘍
詳細な説明
PRIMARY OBJECTIVES:
I. To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.
II. To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.
SECONDARY OBJECTIVES:
I. To determine if capecitabine and oxaliplatin increases the duration of progression-free survival (PFS) compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.
II. To determine if bevacizumab increases the duration of PFS compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.
III. To compare the response rates for capecitabine and oxaliplatin versus carboplatin and paclitaxel in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.
IV. To compare the response rates for bevacizumab versus no bevacizumab in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.
V. To determine the nature and degree of toxicity of capecitabine and oxaliplatin compared with that of carboplatin and paclitaxel in this cohort of patients.
VI. To determine the nature and degree of toxicity of bevacizumab in this cohort of patients.
VII. To compare capecitabine and oxaliplatin versus carboplatin and paclitaxel with respect to changes in patient reported neurotoxicity.
VIII. To determine the impact on quality of life (QOL, as measured by the Functional Assessment of Cancer Therapy-Ovarian [FACT-O] Trial Outcome Index [TOI]) following treatment with the above regimens.
TERTIARY OBJECTIVES:
I. To collect fixed and/or frozen tissue and whole blood for future research studies.
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM I: Patients receive carboplatin intravenously (IV) over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
ARM IV: Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- University of Alabama at Birmingham Cancer Center
-
Mobile、Alabama、アメリカ、36688
- University of South Alabama Mitchell Cancer Institute
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85013
- Saint Joseph's Hospital and Medical Center
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Burbank、California、アメリカ、91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Castro Valley、California、アメリカ、94546
- East Bay Radiation Oncology Center
-
Castro Valley、California、アメリカ、94546
- Valley Medical Oncology Consultants-Castro Valley
-
Emeryville、California、アメリカ、94608
- Bay Area Breast Surgeons Inc
-
Emeryville、California、アメリカ、94608
- Epic Care Partners in Cancer Care
-
Fremont、California、アメリカ、94538
- Valley Medical Oncology Consultants-Fremont
-
Los Angeles、California、アメリカ、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90033
- Los Angeles General Medical Center
-
Martinez、California、アメリカ、94553-3156
- Contra Costa Regional Medical Center
-
Mountain View、California、アメリカ、94040
- El Camino Hospital
-
Oakland、California、アメリカ、94609
- Alta Bates Summit Medical Center - Summit Campus
-
Oakland、California、アメリカ、94609
- Hematology and Oncology Associates-Oakland
-
Oakland、California、アメリカ、94609
- Tom K Lee Inc
-
Oakland、California、アメリカ、94609
- Bay Area Tumor Institute
-
Oakland、California、アメリカ、94602
- Wilma Chan Highland Hospital
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
San Pablo、California、アメリカ、94806
- Doctors Medical Center- JC Robinson Regional Cancer Center
-
Sylmar、California、アメリカ、91342
- Olive View-University of California Los Angeles Medical Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- The Medical Center of Aurora
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
Boulder、Colorado、アメリカ、80303
- Boulder Community Foothills Hospital
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Denver、Colorado、アメリカ、80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver、Colorado、アメリカ、80220
- Rose Medical Center
-
Denver、Colorado、アメリカ、80222
- Western States Cancer Research NCORP
-
Denver、Colorado、アメリカ、80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Englewood、Colorado、アメリカ、80113
- Swedish Medical Center
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Grand Junction、Colorado、アメリカ、81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley、Colorado、アメリカ、80631
- Banner North Colorado Medical Center
-
Lakewood、Colorado、アメリカ、80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton、Colorado、アメリカ、80122
- AdventHealth Littleton
-
Lone Tree、Colorado、アメリカ、80124
- Sky Ridge Medical Center
-
Longmont、Colorado、アメリカ、80501
- Longmont United Hospital
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker、Colorado、アメリカ、80138
- AdventHealth Parker
-
Pueblo、Colorado、アメリカ、81004
- Saint Mary Corwin Medical Center
-
Thornton、Colorado、アメリカ、80229
- North Suburban Medical Center
-
Wheat Ridge、Colorado、アメリカ、80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06102
- Hartford Hospital
-
New Britain、Connecticut、アメリカ、06050
- The Hospital of Central Connecticut
-
Stamford、Connecticut、アメリカ、06904
- Stamford Hospital/Bennett Cancer Center
-
-
Delaware
-
Lewes、Delaware、アメリカ、19958
- Beebe Medical Center
-
Newark、Delaware、アメリカ、19718
- Christiana Care Health System-Christiana Hospital
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta、Georgia、アメリカ、30912
- Augusta University Medical Center
-
Columbus、Georgia、アメリカ、31904
- John B Amos Cancer Center
-
Gainesville、Georgia、アメリカ、30501
- Northeast Georgia Medical Center-Gainesville
-
Savannah、Georgia、アメリカ、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Queen's Medical Center
-
Honolulu、Hawaii、アメリカ、96813
- University of Hawaii Cancer Center
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Bloomington、Illinois、アメリカ、61701
- OSF Saint Joseph Medical Center
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Canton、Illinois、アメリカ、61520
- Graham Hospital Association
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Carthage、Illinois、アメリカ、62321
- Memorial Hospital
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Decatur、Illinois、アメリカ、62526
- Heartland Cancer Research NCORP
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Eureka、Illinois、アメリカ、61530
- Eureka Hospital
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Havana、Illinois、アメリカ、62644
- Mason District Hospital
-
Havana、Illinois、アメリカ、62644
- Illinois CancerCare-Havana
-
Hinsdale、Illinois、アメリカ、60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Macomb、Illinois、アメリカ、61455
- Mcdonough District Hospital
-
Monmouth、Illinois、アメリカ、61462
- Illinois CancerCare-Monmouth
-
Monmouth、Illinois、アメリカ、61462
- Holy Family Medical Center
-
Normal、Illinois、アメリカ、61761
- Carle Cancer Institute Normal
-
Normal、Illinois、アメリカ、61761
- Illinois CancerCare-Community Cancer Center
-
Normal、Illinois、アメリカ、61761
- Carle BroMenn Medical Center
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa、Illinois、アメリカ、61350
- Ottawa Regional Hospital and Healthcare Center
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Pekin、Illinois、アメリカ、61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria、Illinois、アメリカ、61636
- Methodist Medical Center of Illinois
-
Peoria、Illinois、アメリカ、61637
- OSF Saint Francis Medical Center
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peoria、Illinois、アメリカ、61614
- Proctor Hospital
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Peru、Illinois、アメリカ、61354
- Illinois Valley Hospital
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Princeton、Illinois、アメリカ、61356
- Perry Memorial Hospital
-
Rockford、Illinois、アメリカ、61104
- Swedish American Hospital
-
Spring Valley、Illinois、アメリカ、61362
- Illinois CancerCare-Spring Valley
-
-
Indiana
-
Elkhart、Indiana、アメリカ、46515
- Elkhart General Hospital
-
Elkhart、Indiana、アメリカ、46514
- Michiana Hematology Oncology PC-Elkhart
-
Elkhart、Indiana、アメリカ、46514-2098
- Elkhart Clinic
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
Kokomo、Indiana、アメリカ、46904
- Community Howard Regional Health
-
La Porte、Indiana、アメリカ、46350
- IU Health La Porte Hospital
-
Mishawaka、Indiana、アメリカ、46545
- Michiana Hematology Oncology PC-Mishawaka
-
Mishawaka、Indiana、アメリカ、46545
- Cancer Care Partners LLC
-
Mishawaka、Indiana、アメリカ、46545
- Saint Joseph Regional Medical Center-Mishawaka
-
Plymouth、Indiana、アメリカ、46563
- Michiana Hematology Oncology PC-Plymouth
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
South Bend、Indiana、アメリカ、46628
- Northern Indiana Cancer Research Consortium
-
South Bend、Indiana、アメリカ、46617
- South Bend Clinic
-
Westville、Indiana、アメリカ、46391
- Michiana Hematology Oncology PC-Westville
-
-
Iowa
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50316
- Iowa Lutheran Hospital
-
Des Moines、Iowa、アメリカ、50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines、Iowa、アメリカ、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Sioux City、Iowa、アメリカ、51101
- Siouxland Regional Cancer Center
-
Sioux City、Iowa、アメリカ、51102
- Mercy Medical Center-Sioux City
-
Sioux City、Iowa、アメリカ、51104
- Saint Luke's Regional Medical Center
-
West Des Moines、Iowa、アメリカ、50266-7700
- Methodist West Hospital
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Edgewood、Kentucky、アメリカ、41017
- Saint Elizabeth Healthcare Edgewood
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Pikeville、Kentucky、アメリカ、41501
- Pikeville Medical Center
-
-
Louisiana
-
Lafayette、Louisiana、アメリカ、70503
- Cancer Center of Acadiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
Elkton、Maryland、アメリカ、21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
-
Michigan
-
Escanaba、Michigan、アメリカ、49829
- OSF Saint Francis Hospital and Medical Group
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49048
- Beacon Kalamazoo
-
Niles、Michigan、アメリカ、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau、Missouri、アメリカ、63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City、Missouri、アメリカ、65109
- MU Health Care Goldschmidt Cancer Center
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63131
- Missouri Baptist Medical Center
-
-
Montana
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Billings、Montana、アメリカ、59101
- Saint Vincent Healthcare
-
Billings、Montana、アメリカ、59102
- Montana Cancer Consortium NCORP
-
Billings、Montana、アメリカ、59102
- Saint Vincent Frontier Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Butte、Montana、アメリカ、59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Havre、Montana、アメリカ、59501
- Northern Montana Hospital
-
Helena、Montana、アメリカ、59601
- Saint Peter's Community Hospital
-
Kalispell、Montana、アメリカ、59901
- Glacier Oncology PLLC
-
Kalispell、Montana、アメリカ、59901
- Kalispell Medical Oncology
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、アメリカ、59802
- Montana Cancer Specialists
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital University Medical Center
-
Mount Holly、New Jersey、アメリカ、08060
- Virtua Memorial
-
Voorhees Township、New Jersey、アメリカ、08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
-
New York
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Goldsboro、North Carolina、アメリカ、27534
- Wayne Memorial Hospital
-
Hendersonville、North Carolina、アメリカ、28792
- AdventHealth Hendersonville
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
Winston-Salem、North Carolina、アメリカ、27104
- Southeast Clinical Oncology Research Consortium NCORP
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Sanford Bismarck Medical Center
-
Bismarck、North Dakota、アメリカ、58501
- Mid Dakota Clinic
-
Bismarck、North Dakota、アメリカ、58501
- Saint Alexius Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- Summa Health System - Akron Campus
-
Bellefontaine、Ohio、アメリカ、43311
- Mary Rutan Hospital
-
Canton、Ohio、アメリカ、44710
- Aultman Health Foundation
-
Chillicothe、Ohio、アメリカ、45601
- Adena Regional Medical Center
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati、Ohio、アメリカ、45242
- Bethesda North Hospital
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44109
- MetroHealth Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、アメリカ、43228
- Doctors Hospital
-
Columbus、Ohio、アメリカ、43213
- Mount Carmel East Hospital
-
Columbus、Ohio、アメリカ、43215
- Grant Medical Center
-
Columbus、Ohio、アメリカ、43222
- Mount Carmel Health Center West
-
Columbus、Ohio、アメリカ、43215
- Columbus NCI Community Oncology Research Program
-
Delaware、Ohio、アメリカ、43015
- Grady Memorial Hospital
-
Kettering、Ohio、アメリカ、45429
- Kettering Medical Center
-
Lancaster、Ohio、アメリカ、43130
- Fairfield Medical Center
-
Marietta、Ohio、アメリカ、45750
- Marietta Memorial Hospital
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Mentor、Ohio、アメリカ、44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Mount Vernon、Ohio、アメリカ、43050
- Knox Community Hospital
-
Newark、Ohio、アメリカ、43055
- Licking Memorial Hospital
-
Portsmouth、Ohio、アメリカ、45662
- Southern Ohio Medical Center
-
Springfield、Ohio、アメリカ、45504
- Springfield Regional Medical Center
-
Westerville、Ohio、アメリカ、43081
- Saint Ann's Hospital
-
Zanesville、Ohio、アメリカ、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington、Pennsylvania、アメリカ、19001
- Jefferson Abington Hospital
-
Bethlehem、Pennsylvania、アメリカ、18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Hazleton、Pennsylvania、アメリカ、18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
State College、Pennsylvania、アメリカ、16801
- Geisinger Medical Group
-
Wilkes-Barre、Pennsylvania、アメリカ、18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women and Infants Hospital
-
-
South Carolina
-
Anderson、South Carolina、アメリカ、29621
- AnMed Health Cancer Center
-
Anderson、South Carolina、アメリカ、29621
- AnMed Health Hospital
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Spartanburg、South Carolina、アメリカ、29303
- Spartanburg Medical Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37920
- University of Tennessee - Knoxville
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Galveston、Texas、アメリカ、77555-0565
- University of Texas Medical Branch
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77030
- Memorial Hermann Texas Medical Center
-
-
Virginia
-
Danville、Virginia、アメリカ、24541
- Danville Regional Medical Center
-
Fredericksburg、Virginia、アメリカ、22408
- Hematology Oncology Associates of Fredericksburg Inc
-
Lynchburg、Virginia、アメリカ、24501
- Centra Alan B Pearson Regional Cancer Center
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay、Wisconsin、アメリカ、54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Green Bay、Wisconsin、アメリカ、54301-3526
- Green Bay Oncology at Saint Vincent Hospital
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Manitowoc、Wisconsin、アメリカ、54221
- Holy Family Memorial Hospital
-
Marinette、Wisconsin、アメリカ、54143
- Bay Area Medical Center
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Oconto Falls、Wisconsin、アメリカ、54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit、Wisconsin、アメリカ、53066
- Aurora Medical Center in Summit
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
-
Wyoming
-
Casper、Wyoming、アメリカ、82609
- Rocky Mountain Oncology
-
Sheridan、Wyoming、アメリカ、82801
- Welch Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with a histologic diagnosis of mucinous adenocarcinoma of the ovary or fallopian tube with either optimal (=< 1 cm residual disease) or suboptimal residual disease following initial surgery; patients may have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or no measurable disease
- All patients must have had appropriate surgery including appendectomy (unless patient has history of prior appendectomy) for ovarian or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage
- Patients must have stage II-IV disease (new or recurrent-chemonaïve; no brain metastasis) or recurrent stage I disease (chemonaïve)
- Newly diagnosed patients must begin protocol therapy within 10 weeks of primary debulking; for stage I recurrent patients (chemonaïve), they should begin protocol therapy within 14 days of randomization
- Patients must have a negative colonoscopy within 1 year of enrolling in the study
- Absolute neutrophil count (ANC) >= 1,500/mcl
- White blood cell (WBC) count >= 3,000/mcl
- Platelets >= 100,000/mcl
- Hemoglobin (Hgb) >= 10 g/dl (can be post transfusion)
- Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) OR creatinine clearance > 50 cc/min
- Bilirubin =< 1.5 x ULN
- Serum glutamic oxaloacetic transaminase (SGOT) =< to 2.5 x ULN
- Alkaline phosphatase =< to 2.5 x ULN
- Neuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1
- Urine dipstick for proteinuria < 2+; if urine dipstick is >= 2+, 24 hour urine must demonstrate =< 1 g protein in 24 hours OR patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
- Prothrombin time (PT) =< 1.5 x ULN
- Activated prothrombin time (APTT) =< 1.5 x ULN
- Patients of childbearing potential must agree to practice an effective form of birth control during study treatment and for six months after completion of treatment
- Patients who have met the pre-entry requirements
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients with Gynecologic Oncology Group (GOG) performance grade of 0, 1 or 2
- Patients with life expectancy > 3 months
Exclusion Criteria:
- Patients with known colon cancer or history of colon cancer
- Patients with primary peritoneal carcinoma
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
- Patients who have received chemotherapy, radiotherapy or any investigational treatment for a gynecologic cancer (does include breast cancer) or colorectal cancer prior to enrollment
- Patients with a major surgical procedure anticipated during the course of the study; this includes but is not limited to: abdominal surgery (laparotomy or laparoscopy) such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery; please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
- Patients may have minor surgical procedures (i.e., mediport insertion) fine needle aspiration or core biopsies as long as it is performed > 7 days prior to the first date of bevacizumab therapy and there is no evidence of wound disruption or impaired healing
- Patients with surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for fact that bevacizumab can be omitted from first cycle of chemotherapy)
- Patients with a history of abdominal fistula or perforation within the past 12 months
- Patients with a current, serious, non-healing wound, ulcer, or bone fracture; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
- Patients with known hypersensitivity to Chinese hamster cell products or other recombinant human or humanized antibodies
- Patients with mixed epithelial ovarian cancer histology
- Patients with tumors of low malignant potential
- History or evidence of upon physical examination of central nervous system (CNS) disease, including history of primary brain tumor or any history of brain metastases, or seizures not controlled with standard medical therapy
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 100 mm Hg; patients with a history of hypertension are permitted
- Myocardial infarction or unstable angina within 12 months of the first date of bevacizumab therapy
- New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication; women who have received prior treatment with anthracycline (including doxorubicin and/or liposomal doxorubicin) and have an ejection fraction < 50% will be excluded from the study
- Grade 1, category 2 or greater, peripheral vascular disease; patient cannot have anything worse than mild, symptomatic claudication with exercise
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of bevacizumab therapy
- History of pulmonary embolism or deep vein thrombosis in the past 6 months
- Previous history of malabsorption or other conditions preventing oral treatment
- Patients who are pregnant or nursing
- Patients with acute hepatitis or active infection that requires parenteral antibiotics
- Patients with active bleeding or pathologic conditions that carry a high risk of bleeding such as a known bleeding disorder, coagulopathy or tumor involving the major vessels
- Patients taking warfarin
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (carboplatin and paclitaxel)
Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Correlative studies Ancillary studies
他の名前:
|
|
実験的:Arm II (oxaliplatin and capecitabine)
Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies Ancillary studies
他の名前:
Given PO
他の名前:
Given IV
他の名前:
|
|
実験的:Arm III (carboplatin, paclitaxel, bevacizumab)
Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Correlative studies Ancillary studies
他の名前:
Given IV
他の名前:
|
|
実験的:Arm IV (oxaliplatin, capecitabine, bevacizumab)
Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. |
Correlative studies Ancillary studies
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:Up to five years
|
Overall survival is defined as the duration of time from study entry to time of death, or the date of last contact. |
Up to five years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participants With Grade 1 or Higher Non-serious Adverse Effects Assessed by CTCAE Version 4.0
時間枠:Every cycle while on treatment, up to 5 years
|
Grade 1 or higher non-serious adverse events were graded by CTC AE v 4. |
Every cycle while on treatment, up to 5 years
|
|
Progression-free Survival
時間枠:Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
|
Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
|
|
Objective Tumor Response
時間枠:CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years
|
Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR),.>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR |
CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years
|
|
Patient Reported Neurotoxicity
時間枠:baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
|
Patient reported neurotoxicity symptoms as measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity. |
baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
|
|
Patient Reported Quality of Life
時間枠:baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
|
Patient reported quality of life was measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). Each item in the FACT-O TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. The FACT-O TOI score ranges 0-100 with a large score suggests better QOL |
baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Numbers and Percentages of Patients With Mutations in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Oncogene
時間枠:Baseline
|
Will be tabulated. Interactions between the mutational status of the KRAS oncogene and treatment will be examined. |
Baseline
|
協力者と研究者
捜査官
- 主任研究者:David M Gershenson、NRG Oncology
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 生殖器疾患、女性
- 内分泌腺腫瘍
- 卵巣疾患
- 付属器疾患
- 性器腫瘍、女性
- 性腺疾患
- 卵管疾患
- 卵巣腫瘍
- 卵管腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 調整錯体
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヘルスケアの経済学と組織
- ヌクレオシド
- ウラシル
- ピリミジノン
- 免疫グロブリンアイソタイプ
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- デオキシリボヌクレオシド
- フルオロウラシル
- 経済
- カペシタビン
- オキサリプラチン
- ベバシズマブ
- カルボプラチン
- パクリタキセル
- 免疫グロブリンG
- ジスルフィド
- 税金
その他の研究ID番号
- NCI-2011-02516
- U10CA180868 (米国 NIH グラント/契約)
- U10CA027469 (米国 NIH グラント/契約)
- NCI-2011-02516 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- GOG-0241 (その他の識別子:CTEP)
- CDR0000667089
- GOG-0241
- GOG-0241 (その他の識別子:NRG Oncology)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。